Recently, Great Bay Bio (GBB) partnered with Professor JZ Chen from the Koch Institute for Integrative Cancer Research at MIT to advance the discovery of a novel tumor-targeting antibody. This partnership aims to provide innovative antibody drug solutions for treating multiple solid tumors. This collaboration marks a new milestone for GBB in the application of cutting-edge international biotechnology.

This collaboration combines GBB's applied advantages in the field of drug discovery with the extensive expertise of Professor Chen in tumor-specific antibody discovery. Together, we aim to drive the discovery of novel antibodies targeting tumor antigens and accelerate the development of innovative therapeutic solutions for various solid tumors.

GBB is a biotech company that drives drug development using advanced technologies such as AI, big data mining, and automation, with a vision of “Global Bioprocessing Made Simpler and More efficient." In the process of internationalization, GBB has established partnerships with several MNCs in the life sciences, specialty chemicals, and pharmaceutical CDMO sectors. Additionally, GBB has launched the world’s first commercialized site-specific integration cell line development platform (AlfaCell), which has enabled customers to secure clinical trial approvals from both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).

Professor Chen is professor of biology at MIT, Singapore Research Professor, and intramural faculty at the Koch Institute. He is dedicated to studying the immune system and its applications in cancer immunotherapy and vaccine development. He has extensive research experience in immunology, molecular and cellular mechanisms, humanized mice, and target discovery, and antibody-mediated therapies. Professor Chen has published numerous scholarly papers in prestigious journals such as Nature, Nature Biomedical Engineering, and Cell. Professor Chen was elected as Fellow by the American Association for the Advancement of Science (AAAS) for his outstanding contributions to scientific research, technological innovation, education, and public service.

Professor Chen stated, “Our laboratory aims to deeply explore efficient and diverse tumor treatment approaches. By leveraging Great Bay Bio’s extensive expertise in intelligent drug development, this collaboration will drive groundbreaking progress in the field of tumor-specific antibody discovery, providing cancer patients with more effective treatment solutions.”